Native GIP
Metabolic
ABOUT
Native glucose-dependent insulinotropic polypeptide (GIP) is an endogenous incretin hormone. A small randomised trial evaluated native GIP alone or with semaglutide in people with type 2 diabetes; the predefined glucose outcome was not improved.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Glucose-dependent insulinotropic polypeptide is a 42-amino-acid incretin hormone released from duodenal K cells after eating, acting at the GIP receptor to potentiate glucose-dependent insulin secretion. Its role is genuinely unsettled: GIP-receptor agonism is part of tirzepatide and retatrutide, yet GIP-receptor antagonism is also being developed for obesity, and both approaches have supportive data. Native GIP is not itself a therapeutic agent.
PHARMACOKINETICS
Native GIP is rapidly inactivated by dipeptidyl peptidase-4, giving a plasma half-life of minutes. That instability is why a therapeutic application needs either continuous infusion or an engineered analogue - it cannot be given as an ordinary injection.
REVIEW
PUBLISHED PAIR RECORDS
with Semaglutide
Direct native-GIP plus semaglutide studyA small randomised trial studied native GIP with semaglutide in people with type 2 diabetes. The prespecified glucose outcome was not improved by the added native GIP. This does not establish how other GIP/GLP-1 products, doses, routes, or formulations behave together.
Reviewed 19 Aug 2026with Tirzepatide
Overlapping incretin-pathway activityTirzepatide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Retatrutide
Overlapping incretin-pathway activityRetatrutide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Survodutide
Overlapping incretin-pathway activitySurvodutide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Mazdutide
Overlapping incretin-pathway activityMazdutide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Cagrilintide
Overlapping incretin-pathway activityCagrilintide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with MK-677
Opposing effects on glucose regulationMK-677 raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Native GIP acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Tesamorelin
Opposing effects on glucose regulationTesamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Native GIP acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with CJC-1295 with DAC
Opposing effects on glucose regulationCJC-1295 with DAC raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Native GIP acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Sermorelin
Opposing effects on glucose regulationSermorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Native GIP acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Ipamorelin
Opposing effects on glucose regulationIpamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Native GIP acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with PT-141
Additive delay of gastric emptyingBremelanotide (PT-141) labelling states that it slows gastric emptying and may reduce the rate and extent of absorption of concomitantly administered oral medicines - patients are advised to avoid it alongside oral drugs that depend on threshold concentrations, and to avoid oral naltrexone products entirely because exposure is significantly decreased. Approved GLP-1 labelling carries the same gastric-emptying caution. Scheduling Native GIP alongside PT-141 therefore stacks two agents that independently delay gastric emptying, which matters most for any oral medicine taken in the same window. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Liraglutide
Overlapping incretin-pathway activityLiraglutide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Exenatide
Overlapping incretin-pathway activityExenatide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Dulaglutide
Overlapping incretin-pathway activityDulaglutide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Pramlintide
Overlapping incretin-pathway activityPramlintide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Teduglutide
Opposing effects on intestinal absorptionTeduglutide is a GLP-2 analogue that increases villus height and crypt depth, enlarging absorptive surface area; its labelling records a potential for increased absorption of concomitant oral medicines and advises monitoring where a drug is titrated or has a narrow therapeutic index, since the oral drug may need its dose reduced. Native GIP works in the opposite direction on the same variable - incretin-pathway labelling and pharmacology describe delayed gastric emptying, which slows the rate at which an oral medicine reaches the small intestine. One agent is enlarging the absorptive surface while the other is changing the timing of delivery to it, so the net effect on any co-administered oral medicine is not predictable from either alone. The metabolic agent in this pair is investigational, so no labelled combination guidance exists for it. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with CJC-1295 / Ipamorelin blend
Inherited from a component of this blendCJC-1295 / Ipamorelin blend contains Ipamorelin, and the catalogue holds a curated pair record between that component and Native GIP: Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 with DAC / Ipamorelin blend
Inherited from a component of this blendCJC-1295 with DAC / Ipamorelin blend contains CJC-1295 with DAC and Ipamorelin, and the catalogue holds a curated pair record between those components and Native GIP: CJC-1295 with DAC (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Sermorelin / Ipamorelin blend
Inherited from a component of this blendSermorelin / Ipamorelin blend contains Sermorelin and Ipamorelin, and the catalogue holds a curated pair record between those components and Native GIP: Sermorelin (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Kyinsu
Inherited from a component of this blendKyinsu contains Semaglutide, and the catalogue holds a curated pair record between that component and Native GIP: Semaglutide (direct native-gip plus semaglutide study). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CagriSema
Inherited from a component of this blendCagriSema contains Semaglutide and Cagrilintide, and the catalogue holds a curated pair record between those components and Native GIP: Semaglutide (direct native-gip plus semaglutide study); Cagrilintide (overlapping incretin-pathway activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
Native GIP has been given to people under trial conditions and did not work. A single-centre double-blind randomised placebo-controlled trial delivered a 6-week subcutaneous infusion of native GIP, alone and as an add-on to semaglutide, in people with type 2 diabetes; the predefined glucose outcome was not improved. There is no approved native GIP product. The clinical success in this area belongs to the engineered dual and triple agonists (tirzepatide, retatrutide), whose GIP-receptor component cannot be evaluated in isolation from their GLP-1 activity.
REPORTED EFFECTS
The 6-week infusion trial is the only controlled human safety exposure curated here and is far too small to characterise the profile of administered native GIP. Statements about "GIP" drawn from tirzepatide trials describe a dual agonist, not this peptide. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.
RESEARCH LIMITATIONS
This record is for native GIP only. It is not evidence for tirzepatide, retatrutide, other GIP/GLP-1 co-agonists, or compounded products. The trial was short and small, so it does not establish broad benefit or safety.
CURATED SOURCES · 3